



DTOS Rec'd PCT/PTO 09 AUG 2002

Attorney Docket No. 57127 (46342)

# 4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S) Takuya Watanabe, et al. EXAMINER: Not Yet Assigned  
U.S.S.N.: 10/070,240 GROUP: Not Yet Assigned  
FILED (U.S.): February 27, 2002 Conf. No. 2962  
FOR: NOVEL G PROTEIN-COUPLED RECEPTOR PROTEIN AND DNA  
THEREOF

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as Express Mail Label No. **EL 933049045 US** in an envelope addressed to: BOX SEQUENCE, Commissioner for Patents, Washington, D.C. 20231 on August 9, 2002.

By:   
Helen Murray Tarbi

BOX SEQUENCE  
Commissioner for Patents  
Washington, D.C. 20231

Sir/Madam:

**RESPONSE TO NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. § 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)**

The following is in response to the Notification Of Missing Requirements Under 35 U.S.C. § 371 In The United States Designated/Elected Office (DO/EO/US), mailed June 12, 2002, in the above-referenced application.

Enclosed herewith for filing in the subject application are the following:

1. A copy of the Notification Of Missing Requirements;
2. Corrected Paper Copy of Sequence Listing;
3. Computer Readable Form (CRF) of Sequence Listing;

4. Copy of Error Report indicating errors on Paper Copy of Sequence Listing;
5. Amendment directing entry of Paper Copy of Sequence Listing into specification [included in this paper];
6. Statement Accompanying Submission Of Sequence Listing Under 37 C.F.R. § 1.821(g) (included in this paper);
7. Amendment in Response to Notice Under 37 CFR §§ 1.821-825; and
8. A return receipt postcard.

**AMENDMENT DIRECTING ENTRY OF SEQUENCE LISTING**

At the last page of the specification, please enter the attached paper copy of the Sequence Listing (15 pages) and number the pages as appropriate.

**STATEMENT ACCOMPANYING SUBMISSION OF SEQUENCE LISTING**

Provided herewith is a Paper Copy of a Sequence Listing for the nucleotide and/or amino acid sequence(s) in this application. An amendment directing entry of the Paper Copy of the Sequence Listing into the specification is provided above. Each Sequence has been assigned a separate identifier as required in 37 C.F.R. § 1.821(c) and 37 C.F.R. §§ 1.822 and 1.823 (see attached amendment).


Applicants further provide a Computer Readable Form (CRF) corresponding to the Paper Copy of the Sequence Listing provided herewith. Pursuant to 37 C.F.R. § 1.821(g), Applicants' agent hereby states that the CRF corresponds exactly to the Paper Copy of the Sequence Listing provided herewith. Applicants' agent further hereby states that the contents of the Paper Copy of the Sequence Listing and CRF do not go beyond the disclosure in the Application as filed and do not introduce new matter.

Attorney Docket No. 57127 (46342)  
U.S.S.N. 10/070,240  
Filed: February 27, 2002  
Page 3 of 3

If for any reason, the fee paid is inadequate or credit is owed for any excess fee paid, you are hereby authorized and requested to charge Deposit Account No. **04-1105**.

Respectfully submitted,

Date: August 9, 2002

  
\_\_\_\_\_  
Dianne M. Rees, Ph.D.  
(Reg. No. 45,281)  
EDWARDS & ANGELL, LLP  
P.O. Box 9169  
Boston, MA 02209

Telephone: 617-439-4444  
Customer No. 21874



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents, Box PCT  
 United States Patent and Trademark Office  
 Washington, D.C. 20231  
 www.uspto.gov

U.S. APPLICATION NUMBER NO. 10/070,240	FIRST NAMED APPLICANT Takuya Watanabe	ATTY. DOCKET NO. 57127 (46342)
---	--	-----------------------------------

21874

DIKE, BRONSTEIN, ROBERTS AND CUSHMAN,  
 INTELLECTUAL PROPERTY PRACTICE GROUP  
 EDWARDS & ANGELL, LLP.  
 P.O. BOX 9169  
 BOSTON, MA 02209

INTERNATIONAL APPLICATION NO.

PCT/JP00/05685

I.A. FILING DATE

PRIORITY DATE

08/24/2000


08/27/1999

CONFIRMATION NO. 2962

371 FORMALITIES LETTER



\*OC000000008253727\*



Date Mailed: 06/12/2002

### NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fees
- Priority Document
- Assignee Statement
- Biochemical Sequence Listing
- Copy of IPE Report
- Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- Information Disclosure Statements
- Oath or Declaration
- Preliminary Amendments

*Sequence Listing Due*

Edwards &amp; Angell LLP

Dike, Bronstein, Roberts &amp; Cushman

101 Federal St. Boston, MA 02110

Date Rec'd 6/20/02Docketed For Aug 12 - Dec 12, 2002By KFDApproved JMR

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

**ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTH FROM THE DATE OF THIS NOTICE OR BY 22 or 32 MONTHS (where 37 CFR 1.495 applies) FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.**

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

The following items **MUST** be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the

requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

- A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
- APPLICANT MUST PROVIDE:
  - An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.
  - A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).

● For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

- A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

SHAKEEL AHMED

Telephone: (703) 305-3659

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/070,240	PCT/JP00/05685	57127 (46342)